Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Efficacy and safety of current drug therapies for invasive aspergillosis.

Tytuł :
Efficacy and safety of current drug therapies for invasive aspergillosis.
Autorzy :
Traunmüller F; J&P Medical Research Ltd., Vienna, Austria.
Popovic M
Konz KH
Smolle-Jüttner FM
Joukhadar C
Pokaż więcej
Źródło :
Pharmacology [Pharmacology] 2011; Vol. 88 (3-4), pp. 213-24. Date of Electronic Publication: 2011 Oct 06.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
Język :
Imprint Name(s) :
Original Publication: Basel (Switzerland) : Karger,
MeSH Terms :
Antifungal Agents/*therapeutic use
Aspergillosis/*drug therapy
Amphotericin B/therapeutic use ; Animals ; Drug Therapy, Combination ; Echinocandins/therapeutic use ; Humans ; Treatment Outcome ; Triazoles/therapeutic use
Substance Nomenclature :
0 (Antifungal Agents)
0 (Echinocandins)
0 (Triazoles)
7XU7A7DROE (Amphotericin B)
Entry Date(s) :
Date Created: 20111012 Date Completed: 20120223 Latest Revision: 20131121
Update Code :
Czasopismo naukowe
Invasive aspergillosis (IA) is a potentially lethal infection that affects mostly immunocompromised patients. The therapeutic goals are to restore leucocyte function and to reduce the fungal burden by effective antifungal agents and, contingently, by surgery. Several drugs for the treatment of IA are currently licensed. The longest known among them is amphotericin B (AmB). In well-performed clinical trials, approximately 30-50% of participants treated with AmB showed complete or partial response. However, this drug is associated with considerable acute and chronic toxicity which was somewhat mitigated by the development of lipid-based formulations. In contrast, voriconazole (VRC) is better tolerated, penetrates well into the central nervous system and may be given intravenously and orally in a sequential manner. The overall rates of favourable response to VRC were similar to that for AmB. Most notably, double-digit rates of complete remission were observed in studies including extraordinarily high proportions of patients with proven IA and specific risk factors. Disadvantages of VRC include the genetically determined interindividual variability of pharmacokinetics and the potential for drug-drug interactions that may require therapeutic drug monitoring. The recently introduced caspofungin (CPF) offers an excellent safety profile, but underperformed in terms of efficacy against mold infections. Other antifungals such as itraconazole and posaconazole are presently recommended as second-line option for the therapy or prophylaxis of (non-)IA. The value of micafungin and anidulafungin remains to be investigated in randomized clinical trials. In guidelines released by relevant medical societies, VRC is recommended as the first choice in the treatment of IA. AmB, preferably given as a liposomal preparation, or combinatory antifungal regimens combining VRC or liposomal AmB with CPF are stated as alternative options.
(Copyright © 2011 S. Karger AG, Basel.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies